Find the right fit for you - faster
Get tailored insights about working at Caribou Biosciences in one quick step.
Caribou Biosciences Snapshot
View siteWebsite
Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company founded by pioneers of CRISPR biology and located in Berkeley, CA. The company is developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies. The eight-year-old company has developed a next-generation, best-in-class CRISPR genome editing technology platform and has a strong intellectual property position. Caribou utilizes its next-generation CRISPR technologies to boost the persistence of off-the-shelf cell therapies with a goal of developing best-in-class therapeutics. The company’s lead program, CB-010, is an allogeneic anti-CD19 CAR-T from which PD-1 has been genetically deleted.
At Caribou, every employee is respected for their unique perspective and background, and we value diversity in our workforce. Everyone on the Caribou team contributes to both problem solving and innovation. The Company’s vision is to advance agile genome editing innovations for the benefit of our communities.
At Caribou, every employee is respected for their unique perspective and background, and we value diversity in our workforce. Everyone on the Caribou team contributes to both problem solving and innovation. The Company’s vision is to advance agile genome editing innovations for the benefit of our communities.
